EUCTR2008-000709-12-ES进行中（未招募）不适用
Estudio prospectivo, abierto, aleatorizado del tratamiento de combinación de MYOCET® más ciclofosfamida y trastuzumab frente a doxorubicina libre más ciclofosfamida sola, seguidos cada uno de docetaxel y trastuzumab, en el entorno neoadyuvante en pacientes con cáncer de mama HER2 positivo que no han recibido tratamiento anteriormente
Cephalon France0 个研究点目标入组 120 人开始时间: 2008年5月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients are included in the study if all of the following criteria are met:
- •(a) Treatment-naïve patients have stage II or III invasive breast cancer
- •histologically/cytologically proven and overexpressing human epidermal growth factor reeptor 2 (HER2) as demonstrated by fluorescence in situ hybridization (FISH).
- •(b) Patients have at least 1 bidimensionally measurable lesion according to the WHO
- •(c) The patient is a woman 18 to 70 years of age, inclusive.
- •(d) Written informed consent is obtained.
- •(e) The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •(f) The patient has an LVEF of at least 55% as assessed by multiple-gated acquisition (MUGA) scan (preferred) or echocardiography.
- •(g) The patient has haematology and serum chemistry laboratory test results within the following ranges:
- •at least 2x10^9 neutrophils/L
- •at least 100x10^9 platelets/L
- •total bilirubin serum concentrations not exceeding the normal laboratory reference range
- •aspartate aminotransferase (AST) serum levels not exceeding 2.5 times the upper limit of normal (ULN)
- •alanine aminotransferase (ALT) serum levels not exceeding 2.5xULN
- •alkaline phosphatase (ALP) serum levels not exceeding 5.0xULN
- •serum creatinine serum levels not exceeding 1.5xULN
- •(h) Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the treatment period and for 4 months after the last administration of study drug. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device, or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- •(i) The patient must be willing and able to comply with study assessments and willing to return to the clinic for further treatment and follow-up as specified in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- •(a) The patient has received previous cancer therapy for breast cancer.
- •(b) The patient has any history of coronary heart failure (CHF), angina pectoris, or myocardial infarction.
- •(c) The patient has uncontrolled hypertension.
- •(d) The patient has infection, peptic ulcer, or unstable diabetes mellitus.
- •(e) The patient has been treated with live virus vaccines within 8 weeks before the first administration of study drug.
- •(f) The patient has impaired hepatic or renal function.
- •(g) The patient is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
- •(h) The patient has used an investigational drug within 1 month before the screening visit.
- •(i) The patient has a known hypersensitivity to any of the study drugs or to their active ingredients.
- •(j) The patient has an inflammatory breast cancer.
- •(k) The patient has any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
研究者
相似试验
进行中（未招募）
不适用
Estudio prospectivo, abierto, aleatorizado y cruzado sobre el efecto de la Hidroxicloroquina, 200mg al día, en factores inflamatorios y metabólicos relacionados con la enfermedad cardiovascular en pacientes infectados por el virus de la inmunodeficiencia humana.” Open label, prospective, randomized, crossed study of the effect of Hidroxychloroquine, 200 mg QD, on inflammatory and metabolic factors related to cardiovascular disease in human immunodeficiency virus infected patientsInfección por el virus de la inmunodeficiencia adquiridaMedDRA version: 9.1Level: LLTClassification code 10020160Term: HIV diseaseEUCTR2007-007018-12-ESCarlos Alonso-Villaverde Lozano, Hospital Universitari Sant Joan de Reus
进行中（未招募）
不适用
Estudio abierto y aleatorizado, comparativo de la tolerabilidad renal de Bondronat® 6 mg I.V. en perfusión de 15 minutos frente a 60 minutos en pacientes con metástasis óseas - Estudio BON15Prevención de las complicaciones óseas en pacientes oncológicos que presentan metástasis óseasClassification code 10049038EUCTR2006-000608-18-ESRoche Farma, S.A.
进行中（未招募）
1 期
Estudio aleatorizado y abierto, comparativo de la seguridad y la eficacia del cambio de un inhibidor de la calcineurina a sirolimus frente a la continuación del uso de un inhibidor de la calcineurina en trasplantados cardiacos con insuficiencia renal de grado leve a moderado A Randomized, Open-Label Study to Compare the Safety and Efficacy of ConversionFrom a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a CalcineurinInhibitor in Cardiac Transplant Recipients With Mild to Moderate Renal InsufficiencyTrasplantados cardiacos con insuficiencia renal de grado leve a moderado Cardiac transplant recipients with mild to moderate renal insufficiency.EUCTR2006-002420-41-ESWyeth Research, Division of Wyeth Pharmaceuticals, Inc.200
进行中（未招募）
不适用
Estudio prospectivo, abierto, no aleatorizado y multicéntrico para investigar la seguridad y la tolerabilidad del voriconazol como tratamiento primario de la aspergilosis invasiva y de infecciones por hongos filamentosos, entre ellos, especies de Scedosporium o Fusarium, en pacientes pediátricosA PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTSTratamiento de la aspergilosis invasiva y de la infección por hongos filamentosos raros, como las especies de Scedosporium o Fusarium.Treatment of proven or probable invasive aspergillosis (IA) and rare molds such asScedosporium or Fusarium species.MedDRA version: 9.1Level: LLTClassification code 10003488Term: AspergillosisMedDRA version: 9.1Level: LLTClassification code 10051919Term: Fusarium infectionMedDRA version: 9.1Level: LLTClassification code 10059045Term: Scedosporium infectionEUCTR2008-005275-10-ESPfizer, S.A.36
进行中（未招募）
1 期
?Estudio aleatorizado, controlado y abierto, en el que se compara la eficacia y la seguridad de la sustitución de una medicación estimulante por atomoxetina (transición lenta frente a transición rápida), en niños y adolescentes ambulatorios, con trastorno por déficit de atención/hiperactividad (TDAH), según los criterios DSM-IV?A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD) - LYFJTrastorno de Deficit de Antencion/ HiperactividadMedDRA version: 9.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderEUCTR2008-001767-11-ESilly S.A.111